10x Genomics (TXG) Misses Q4 EPS by $3.64, Revenues Beat; Offers FY21 Revenue Mid-Point Guidance Below Consensus

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 11/4/2026

1. AMD
2. BKNG
3. AMGN
4. DOX
5. DUOL
6. SWKS
7. ANET
8. SPY
9. XYZ
10. CVS

Go back to 10x Genomics (TXG) Misses Q4 EPS by $3.64, Revenues Beat; Offers FY21 Revenue Mid-Point Guidance Below Consensus

10x Genomics Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Outlook for 2021

February 17, 2021 4:03 PM EST

Q4 2020 revenue growth of 49% over prior year

PLEASANTON, Calif., Feb. 17, 2021 (GLOBE NEWSWIRE) -- 10x Genomics, Inc. (Nasdaq: TXG) today reported financial results for the fourth quarter and full year ended December 31, 2020 and provides outlook for full year 2021.

Recent Highlights

Revenue was $298.8 million for the full year and $112.2 million for the fourth quarter of 2020, representing 22% and 49% increases over the corresponding periods of 20192,412 Chromium instruments sold as of December 31, 2020More than 2,200... More